Table 5.
Baseline characteristics by treatment; incident users ever exposed to treatment
| Ustekinumab [N = 1005] | Adalimumab [N = 759] | |
|---|---|---|
| Age, years | 46.2 ± 13.58 | 46.8 ± 13.94 |
| Age category, years | ||
| 18–24 | 60 (6.0) | 36 (4.7) |
| 25–34 | 155 (15.4) | 128 (16.9) |
| 35–44 | 235 (23.4) | 160 (21.1) |
| 45–54 | 271 (27.0) | 204 (26.9) |
| 55–64 | 196 (19.5) | 154 (20.3) |
| ≥ 65 | 88 (8.8) | 77 (10.1) |
| Median duration of PsO, years | 16.8 | 10.4 |
| Psoriatic arthritis | 311 (30.9) | 233 (30.7) |
| Confirmed by specialist | 162 (16.1) | 85 (11.2) |
| Obesity class II/III | 238 (24.0) | 196 (26.1) |
| Historical peak | ||
| %BSA with PsO | 33.8 ± 25.28 | 28.2 ± 24.12 |
| Systemic therapy, n | 682 | 573 |
| 223 (32.7) | 147 (25.7) | |
| PGA score of 4/5, n | 554 | 462 |
| 215 (38.8) | 165 (35.7) |
BSA body surface area, PGA Physician Global Assessment, PsO psoriasis, SD standard deviation
Data are expressed as n (%) or mean ± SD, unless otherwise specified